Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. [electronic resource]
Producer: 20160707Description: 411-9 p. digitalISSN:- 1097-0142
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Axitinib
- Bevacizumab -- administration & dosage
- Carcinoma, Renal Cell -- blood
- Databases, Factual
- Diarrhea -- chemically induced
- Drug Administration Schedule
- Fatigue -- chemically induced
- Female
- Hand-Foot Syndrome -- etiology
- Humans
- Imidazoles -- administration & dosage
- Indazoles -- administration & dosage
- Indoles -- administration & dosage
- Kaplan-Meier Estimate
- Kidney Neoplasms -- blood
- Male
- Middle Aged
- Models, Statistical
- Molecular Targeted Therapy -- adverse effects
- Mucositis -- chemically induced
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Predictive Value of Tests
- Pyrimidines -- administration & dosage
- Pyrroles -- administration & dosage
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Sorafenib
- Sulfonamides -- administration & dosage
- Sunitinib
- Vascular Endothelial Growth Factor A -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.